Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for sec...

Celý popis

Podrobná bibliografia

Vydané v:	Blood advances Ročník 4; číslo 19; s. 4898 - 4911
Hlavní autori:	Locke, Frederick L., Rossi, John M., Neelapu, Sattva S., Jacobson, Caron A., Miklos, David B., Ghobadi, Armin, Oluwole, Olalekan O., Reagan, Patrick M., Lekakis, Lazaros J., Lin, Yi, Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen, Bot, Adrian
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 13.10.2020 American Society of Hematology
Predmet:	Antigens, CD19 - therapeutic use Humans Immunobiology and Immunotherapy Immunotherapy, Adoptive Inflammation Tumor Burden
ISSN:	2473-9529, 2473-9537, 2473-9537
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!